Search Results 11-20 of 25 for Capsule

1. A Study of the Safety and Drug/Body Interactions of LAM-002A for Patients with Non-Hodgkin's Lymphoma - Mayo Clinic

   A Study of the Safety and Drug/Body Interactions of LAM-002A for Patients with Non-Hodgkin's Lymphoma - Mayo Clinic Overview Tab Title Description Study type Interventional Study phase I Study IDs Study type Interventional Describes the nature of a c...

2. Minimally-Invasive Detection of Barrett's Esophagus and Barrett's Esophagus Related Dysplasia/Carcinoma - Mayo Clinic

   Study IDs Site IRB Rochester, Minnesota: 15-004540 Jacksonville, Florida: 15-004540 Scottsdale/Phoenix, Arizona: 15-004540 Austin, Minnesota: 15-004540 NCT ID: NCT02560623 Sponsor Protocol Number: 15-004540 About this study This study will evaluate i...

3. Effectiveness of Deep Brain Stimulation for Treating People with Treatment Resistant Obsessive-Compulsive Disorder - Mayo Clinic

   Nuttin et al, who published the first DBS for OCD series, found promising results using a capsule target immediately rostral to the anterior commissure extending into adjacent ventral capsule/ventral striatum (VC/VS)...

4. A Study to Evaluate Budesonide in Patients with Immune Mediated Enteropathies - Mayo Clinic

   We describe outcomes in patients treated with open-capsule budesonide (OB), including those for whom IM treatment failed.

5. The Microenvironment in Barrett's Esophagus - Mayo Clinic

   Prior to endoscopy each subject will undergo three minimally invasive potential screening and surveillance tests: saliva (oral microbiome), breath test (exhaled volatile organic compounds), and tethered capsule sponge sampling (methy...

6. A Pivotal Study of the Premia Spine TOPS™ System - Mayo Clinic

   Study IDs Site IRB Rochester, Minnesota: 16-009345 NCT ID: NCT03012776 Sponsor Protocol Number: CL-2830 About this study The purpose of this trial is to assess whether the Total Posterior Spine System (TOPS System) is more effective than transforamin...

7. Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy - Mayo Clinic

   Study IDs Site IRB Scottsdale/Phoenix, Arizona: 13-008108 NCT ID: NCT01994889 Sponsor Protocol Number: B3461028 About this study This study will investigate the efficacy, safety, and tolerability of an oral dose of 20 mg or 80 mg tafamidis meglumine ...

8. A Study of DZB-CS-301 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma - Mayo Clinic

   Subjects will be dosed orally once per day at 300 mg of ARQ 087 capsules. more information --> More information Publications Publications are currently not available Study Results Summary Not yet available Supplemental Study Informat...

9. ECOSPOR IV: An Open-Label Extension of Study SERES 0012 Evaluating SER-109 in Subjects With Recurrent Clostridium Difficile Infection - Mayo Clinic

   Study IDs Site IRB Rochester, Minnesota: 17-007209 NCT ID: NCT03183141 Sponsor Protocol Number: SERES-013 About this study Subjects who had a CDI recurrence in Study SERES-012 within 8 weeks of receipt of study drug will receive an oral dose of SER-1...

10. Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy - Mayo Clinic

    Study IDs Site IRB Rochester, Minnesota: 13-000543 NCT ID: NCT01994889 Sponsor Protocol Number: B3461028 About this study This Phase 3 study will investigate the efficacy, safety and tolerability of an oral daily dose of 20 mg or 80 mg tafamidis megl...